Abstract
Background and hypothesis: Multiple contrast‐enhanced echocardiographic studies are to be expected in patients with cardiac ischemic disease, but the sonication process used to produce the echocontrast agent Albunex® may result in new epitopes that could cause an immunogenic response.
Methods: Repeated exposures to intravenous Albunex over a period of time long enough to allow development of an eventual immune reaction were performed in 12 patients while monitoring for lymphocyte transformation, microsphere specific IgE and IgG antibodies, and systemic, pulmonary artery, capillary wedge, and right atrial pressures, as well as cardiac output, left ventricular fractional shortening, and blood gases.
Results: No significant 3H‐thymidine incorporation and thus no specific blastic transformation of the patients' lymphocytes were observed either for high or low Albunex concentrations, corresponding to the expected hepatic and plasma concentrations of microspheres. No formation of micro‐sphere‐specific IgE and IgG antibodies was observed after the first or second Albunex exposure. Furthermore, no clinically significant hemodynamic or respiratory adverse reactions were observed in any patient.
Conclusion: These results suggest that repeated exposures to intravenous Albunex induce no adverse effect on the cellular and humoral immune systems and on left and right heart hemodynamics in patients.
Keywords: Albunex®, contrast echocardiography, immune system, safety microspheres
Full Text
The Full Text of this article is available as a PDF (625.8 KB).
References
- 1. Reisner SA, Ong LS, Lichtenberg GS, Amico AF, Shapiro JR, Allen MN, Meltzer RS: Myocardial perfusion imaging by contrast echocardiography with use of intracoronary sonicated albumin in humans. J Am Coll Cardiol 1989; 14: 660–665 [DOI] [PubMed] [Google Scholar]
- 2. Villanueva FS, Glasheen WP, Sklenar J, Kaul S: Assessment of risk area during coronary occlusion and infarct size after reperfusion with myocardial contrast echocardiography using left and right atrial injections of contrast. Circulation 1993; 88: 596–604 [DOI] [PubMed] [Google Scholar]
- 3. Sanders WE, Cheirif J, Desir R, Zoghbi WA, Hogt BD, Schulz PE, Quinones MA: Contrast opacification of left ventricular myocardium following intravenous administration of sonicated albumin microspheres. Am Heart J 1991; 122: 1660–1665 [DOI] [PubMed] [Google Scholar]
- 4. Quinones MA, Cheirif J: New perspectives for perfusion imaging in echocardiography. Circulation 1991; 83 (suppl III): 104–110 [PubMed] [Google Scholar]
- 5. Kaul S: Clinical applications of myocardial contrast echocardiography. Am J Cardiol 1992; 69: 46H–55H [DOI] [PubMed] [Google Scholar]
- 6. Ten Cate FJ, Cornel JH, Widimsky P, Vletter W, Serruys P, Waaler A: Clinical experience with Albunex: A standard echocontrast agent for intravenous and intracoronary use. Am J Cardiac Imag 1991; 5: 217–223 [PubMed] [Google Scholar]
- 7. Monaghan MJ, Metcalfe JM, Odunlami S, Waaler A, Jewitt DE: Digital radiofrequency echocardiography in the detection of myocardial contrast following intravenous administration of Albunex. Eur Heart J 1993; 14: 1200–1209 [DOI] [PubMed] [Google Scholar]
- 8. Crouse LJ: Sonicated serum albumin in contrast echocardiography: Improved segmental wall motion depiction and implications for stress echocardiography. Am J Cardiol 1992; 69: 42H–45H [DOI] [PubMed] [Google Scholar]
- 9. Porter TR, Xie F, Kricsfeld A, Chiou A, Dabestani A: Improved endocardial border resolution during dobutamine stress echocardiography with intravenous sonicated dextrose albumin. J Am Coll Cardiol 1994; 23: 1440–443 [DOI] [PubMed] [Google Scholar]
- 10. Ten Cate FJ, Widimsky P, Cornel JH, Waldstein DJ, Serruys PW, Waaler A: Intracoronary Albunex: Its effects on left ventricular hemodynamics, function, and coronary sinus flow in humans. Circulation 1993; 88: 2123–2127 [DOI] [PubMed] [Google Scholar]
- 11. Grinstaff MW, Suslick K: Air‐filled proteinaceous microbubbles: Synthesis of an echo‐contrast agent. Proc Natl Acad Sci 1991; 88: 7708–7710 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Hellebust H, Christiansen C, Skotland T: Biochemical characterization of air‐filled albumin microspheres. Biotechnol Appl Biochem 1993; 18: 227–237 [PubMed] [Google Scholar]
- 13. Keller MK, Glasheen W, Kaul S: Albunex: A safe and effective commercially produced agent for myocardial contrast echocardiography. J Am Soc Echocardiogr 1989; 2: 48–52 [DOI] [PubMed] [Google Scholar]
- 14. Ostensen J, Hede R, Myreng Y, Ege T, Holtz E: Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits. Acta Physiol Scand 1992; 144: 307–315 [DOI] [PubMed] [Google Scholar]
- 15. Feinstein SB, Cheirif J, Ten Cate FJ, Silverman PR, Heidenreich PA, Dick C, Desir RM, Armstrong WF, Quinones MA, Shah PM: Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results. J Am Coll Cardiol 1990; 16: 316–324 [DOI] [PubMed] [Google Scholar]
- 16. Geny B, Mettauer B, Muan B, Bischoff P, Epailly E, Piquard F, Eisenmann B, Haberey P: Safety and efficacy of a new transpulmonary echocontrast agent in echocardiographic studies in patients. J Am Coll Cardiol 1993; 22: 1193–1198 [DOI] [PubMed] [Google Scholar]
- 17. Geny BP, Pion PD, Kittleson MD, Bommer WJ: The safety of sonicated human albumin (Albunex) for repeated echocardiographic studies in experimental animals. Circulation 1990; 82 (suppl III): III–95 [Google Scholar]
- 18. Walday P, Ostensen J, Holtz E: Human albumin‐based echocontrast agents: Repeated use in animals may induce anaphylactic reactions. Br J Radiol 1994; 67: 112–113 [DOI] [PubMed] [Google Scholar]
- 19. Maurer PH, Callahan HJ: Immunogens, antigens, and antigenic determinants In Immunological Diseases, p. 1: 13–22. Boston/Toronto: Little, Brown and Company, 1988. [Google Scholar]
- 20. Greenberger PA: Contrast media reactions. J Allergy Clin Immunol 1984; 4: 600–605 [DOI] [PubMed] [Google Scholar]
- 21. Kristensen F, Walker C, Joncourt F, Bettens F, de Weck AL: Human lymphocyte proliferation. 1. Correlation between activated and proliferating T‐lymphocytes. Immunol Lett 1982; 5: 59–63 [DOI] [PubMed] [Google Scholar]
- 22. Weier DM, Herzenberg LA, Blackwell C: Handbook of Experimental Immunology, 4th ed. Cellular Immunology, p. 53–70. Cambridge: Blackwell Scientific Publications, 1988. [Google Scholar]
- 23. Torres B, Lavergne J, Diaz AM: Production of monoclonal antibodies to surface antigens from ultrasound‐treated cells (abstr). FASEB 1983; 3: A898 [Google Scholar]
- 24. Martin S, Weltzien HU: T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol 1994; 104: 10–16 [DOI] [PubMed] [Google Scholar]
- 25. Stafford CT, Lobel SA, Fruge BC, Moffitt JE, Hoff RG, Fadel HE: Anaphylaxis to human serum albumin. Ann Allergy 1988; 61: 85–88 [PubMed] [Google Scholar]
- 26. Ruddle NH: Delayed hypersensitivity to soluble antigens in mice. Int Arch Allergy Immunol 1979; 58: 44–52 [DOI] [PubMed] [Google Scholar]
- 27. Walday P, Tolleshaug H, Gjoen T, Kindberg GM, Berg T, Skotland T, Holz E: Biodistribution of air‐filled albumin microspheres in rats and pigs. Biochem J 1994; 299: 437–443 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Barnhart JL, Haradr M, Lyle LR, Saravis CA: Immunologic reactions of human recipients to repeated exposures to Albunex microspheres. Invest Radiol 1991; 26: S192–S193 [DOI] [PubMed] [Google Scholar]
- 29. Christiansen C, Vebner AJ, Muan B, Vik H, Haider T, Nicolaysen M, Skotland T: Lack of an immune response to Albunex, a new ultrasound contrast agent based on air‐filled albumin microspheres. Int Arch Allergy Immunol 1994; 104: 372–379 [DOI] [PubMed] [Google Scholar]
- 30. Littenberg RL: Anaphylactoid reaction to human albumin microspheres. J Nuclear Med 1975; 16: 236–238 [PubMed] [Google Scholar]
- 31. Ring J, Messmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466–469 [DOI] [PubMed] [Google Scholar]